Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam.
Ontology highlight
ABSTRACT: Meloxicam is a thiazole-containing NSAID that was approved for marketing with favorable clinical outcomes despite being structurally similar to the hepatotoxic sudoxicam. Introduction of a single methyl group on the thiazole results in an overall lower toxic risk, yet the group's impact on P450 isozyme bioactivation is unclear. Through analytical methods, we used inhibitor phenotyping and recombinant P450s to identify contributing P450s, and then measured steady-state kinetics for bioactivation of sudoxicam and meloxicam by the recombinant P450s to determine relative efficiencies. Experiments showed that CYP2C8, 2C19, and 3A4 catalyze sudoxicam bioactivation, and CYP1A2 catalyzes meloxicam bioactivation, indicating that the methyl group not only impacts enzyme affinity for the drugs, but a
SUBMITTER: Barnette DA
PROVIDER: S-EPMC7807415 | biostudies-literature | 2021 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA